A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Summary

The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.

Timeline

Start

2017-09-12

Primary completion

2019-07-04

Completion

2019-07-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications